H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synlogic (NASDAQ:SYBX) Inc on Monday, setting a price target of $13, which is approximately 496.33% above the present share price of $2.18.
Selvaraju expects Synlogic Inc to post earnings per share (EPS) of -$0.37 for the second quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Synlogic, with an average price target of $13.
The analysts price targets range from a high of $13 to a low of $13.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $1.23 million and a net profit of -$13.48 million. The company's market cap is $70.76 million.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is a 5-star analyst with an average return of 22.1% and a 55.8% success rate.
Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.